# Arm's-length lenders

Type: creditor

Source: GetYourBrief — https://getyourbrief.com/entity/arms-length-lenders
Canonical HTML page: https://getyourbrief.com/entity/arms-length-lenders

## Timeline

- **2026-10-26**: Share Hold Period Expires — Four-month-and-one-day hold period ends, allowing newly issued shares to be freely traded, subject to securities laws.
- **2026-10-26**: Share Hold Period Expires — Four-month-and-one-day hold period ends, allowing newly issued shares to be freely traded, subject to securities laws.
- **2026-10-26**: Share Hold Period Expires — Four-month-and-one-day hold period ends, allowing newly issued shares to be freely traded, subject to securities laws.
- **2026-10-26**: Share Hold Period Expires — Four-month-and-one-day hold period ends, allowing newly issued shares to be freely traded, subject to securities laws.
- **2026-06-25**: Anticipated Settlement Date — Settlement expected to close, with 625,000 shares issued and accrued interest paid in cash.
- **2026-06-25**: Anticipated Settlement Date — Settlement expected to close, with 625,000 shares issued and accrued interest paid in cash.
- **2026-06-25**: Anticipated Settlement Date — Settlement expected to close, with 625,000 shares issued and accrued interest paid in cash.
- **2026-06-25**: Anticipated Settlement Date — Settlement expected to close, with 625,000 shares issued and accrued interest paid in cash.
- **2026-06-18**: Debt-for-Equity Agreements Signed — DIAGNOS signs agreements with two lenders to settle C$125,000 in demand loans via equity issuance.
- **2026-06-18**: Debt-for-Equity Agreements Signed — DIAGNOS signs agreements with two lenders to settle C$125,000 in demand loans via equity issuance.
- **2026-06-18**: Debt-for-Equity Agreements Signed — DIAGNOS signs agreements with two lenders to settle C$125,000 in demand loans via equity issuance.
- **2026-06-18**: Debt-for-Equity Agreements Signed — DIAGNOS signs agreements with two lenders to settle C$125,000 in demand loans via equity issuance.

## Recent coverage (4 stories, network-wide)

### How DIAGNOS Converted C$125K Debt into Equity at C$0.20 to Extend Runway
2026-06-21 00:12:03 · Sector: startups · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Startup DIAGNOS, building AI eye diagnostics, used a shares-for-debt settlement to preserve cash and extend its operating runway. The deal adds 625,000 shares at C$0.20 each, showing how early-stage companies can renegotiate obligations to survive.
Full story: https://getstartupbrief.com/story/diagnos-startup-cash-management-debt-equity

### DIAGNOS Dilutes Equity: 625K Shares Issued at C$0.20 to Settle C$125K Debt
2026-06-21 00:11:55 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 4

DIAGNOS announces a C$125K debt settlement through issuance of common shares at C$0.20, a move that conserves cash but dilutes existing shareholders. The transaction awaits TSX Venture approval and introduces a four-month hold period.
Full story: https://getfinancebrief.com/story/diagnos-adk-debt-settlement-dilution

### DIAGNOS Converts C$125K Debt into 625K Shares at C$0.20 to Secure AI Diagnostic Pipeline
2026-06-21 00:11:46 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Biotech company DIAGNOS executes a small debt-for-equity swap, preserving liquidity to sustain its AI-based early detection platform for critical eye conditions. The move reflects the tight capital environment for early-stage diagnostic innovators.
Full story: https://getbiobrief.com/story/diagnos-debt-equity-biotech-cash

### DIAGNOS Preserves Cash with C$125K Debt-for-Equity at C$0.20 to Fuel AI Eye Diagnostics
2026-06-21 00:10:37 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Diagnos Inc. converts C$125K in debt to equity, preserving cash to further develop its AI-powered early detection of eye-related health issues. The move underscores the financial pressures on health AI startups but keeps the clinical mission on track.
Full story: https://gethealthbrief.com/story/diagnos-cash-preservation-ai-eye-diagnostics

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.